Abstract:Abstract Cytokines, such as type-I Interferons (IFN-I), are essential to mount an effective antiviral response. The production of IFN-I is regulated by multiple mechanisms, including ubiquitination of host signaling factors. However, viruses can hijack the ubiquitin (Ub) system to promote viral replication. For example, we recently reported that the E3-Ub ligase TRIM7 ubiquitinates the envelope protein of Zika virus, which increases virus binding to its receptor favoring virus entry. Previous studies suggest that TRIM7 may play dual roles during infection by promoting or inhibiting IFN-I induction depending on the conditions. Here, we used our recently generated Trim7−/− mice to study its physiological role during SARS-CoV-2 (SCoV2) infection. We found that Trim7−/− mice have increased weight loss and lung virus titers compared to WT controls upon infection with SCoV2. We also found a dysregulated innate immune response, which included increased IFN-I induction and reduced neutrophil recruitment and production of inflammatory cytokines such as IL-6 in Trim7−/− mice. We observed a higher frequency of apoptotic cells in Trim7−/− compared to WT mice, specifically in CD45− lung epithelial cells. Mechanistically, using co-immunoprecipitation studies, we confirmed previous reports that TRIM7 interacts with the viral membrane protein (M), which can cause apoptosis. Using recombinant mutants that lack ubiquitination sites on M, we found that TRIM7-mediated ubiquitination of M protects cells against death. This suggests that TRIM7 restricts SCoV2 infection via a novel non-degradative mechanism involving ubiquitination of M. Understanding the role of TRIM7 in inhibiting SCoV2 replication could help develop treatments for COVID-19. Supported by grants from NIH R01 AI166668

TRIM21 promotes ubiquitination of SARS‐CoV‐2 nucleocapsid protein to regulate innate immunity

Targeting TRIM28-mediated SUMOylation of SARS-CoV-2 Nucleocapsid Protein Inhibits SARS-CoV-2 Infection

TRIM28-mediated nucleocapsid protein SUMOylation enhances SARS-CoV-2 virulence

Trim21 modulates endoplasmic reticulum-associated degradation and sensitizes cancer cells to ER stress-induced apoptosis by inhibiting VCP/Npl4/UFD1 assembly

The E3-ligase TRIM7 acts as an antiviral factor by ubiquitinating the SARS-CoV-2 membrane protein to limit apoptosis and virus replication

TRIM7 ubiquitinates SARS-CoV-2 membrane protein to limit apoptosis and viral replication

The Interaction between SARS-CoV-2 Nucleocapsid Protein and UBC9 Inhibits MAVS Ubiquitination by Enhancing Its SUMOylation

Interactome Analysis of the Nucleocapsid Protein of SARS-CoV-2 Virus

TRIM41-Mediated Ubiquitination of Nucleoprotein Limits Vesicular Stomatitis Virus Infection

TRIM41 is required to innate antiviral response by polyubiquitinating BCL10 and recruiting NEMO

A dual-role of SARS-CoV-2 nucleocapsid protein in regulating innate immune response

TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2

Engagement of the G3BP2-TRIM25 Interaction by Nucleocapsid Protein Suppresses the Type I Interferon Response in SARS-CoV-2-Infected Cells

The SARS‐unique domain (SUD) of SARS‐CoV‐2 nsp3 protein inhibits the antiviral immune responses through the NF‐κB pathway

TRIM21 inhibits porcine epidemic diarrhea virus proliferation by proteasomal degradation of the nucleocapsid protein

TRIM21—From Intracellular Immunity to Therapy

Multiple Roles of TRIM21 in Virus Infection

Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity

SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity

E3 ubiquitin ligase TRIM31: A potential therapeutic target

TRIM21 and Fc-engineered antibodies: decoding its complex antibody binding mode with implications for viral neutralization